Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
Singh says Japanese pharma giant's allegations false.
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
While international players may get the same pay, domestic players may face a cut.
Dinesh Thakur says he waved the red flag only after Ranbaxy didn't respond to his concerns.
The government is set to roll out an SMS-based helpline, which will enable consumers to seek information on various brands available in the market for their specific composition, with their prices.
NPPA denies price hike on Sanofi, Novartis, and Allergan products.
Firms meet huge redemption pressure after deducting money from principal amount.
30 per cent of all movies made in Tollywood are produced by chit fund companies.
70 per cent of the total ad market in the state was driven by these companies.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.
A day after about 1,200 media persons from Saradha Group media entities lost their jobs in West Bengal, the state government extended a helping hand. On Wednesday, government officials are set to meet these employees to try and find a resolution to the issue.
Stockists and dealers have been charging more since early March.
Data contradict Swiss drug major's claim that India does not respect IPR.
Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
The idea is to ensure drug companies do not gold-plate drugs to exorbitantly raise prices while introducing those in the market.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances